Impact of source data verification on data quality in clinical trials: an empirical post hoc analysis of three phase 3 randomized clinical trials

被引:34
作者
Andersen, Jeppe Ragnar [1 ]
Byrjalsen, Inger [1 ]
Bihlet, Asger [1 ]
Kalakou, Faidra [2 ]
Hoeck, Hans Christian [3 ]
Hansen, Gitte [1 ]
Hansen, Henrik Bo [1 ]
Karsdal, Morten Asser [1 ]
Riis, Bente Juel [1 ]
机构
[1] Nord Biosci AS, DK-2730 Herlev, Denmark
[2] Univ Copenhagen, Sch Pharmaceut Sci, Fac Hlth & Med Sci, Copenhagen, Denmark
[3] CCBR AS, Aalborg, Denmark
关键词
cost-benefit; data error analysis; monitoring; risk-based monitoring; source data verification;
D O I
10.1111/bcp.12531
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
AimThe aim of this project was to perform an empirical evaluation of the impact of on site source data verification (SDV) on the data quality in a clinical trial database to guide an informed decision on selection of the monitoring approach. MethodsWe used data from three randomized phase III trials monitored with a combination of complete SDV or partial SDV. After database lock, individual subject data were extracted from the clinical database and subjected to post hoc complete SDV. Error rates were calculated with focus on the degree of on study monitoring and relevance and analyzed for potential impact on end points. ResultsData from a total of 2566 subjects including more than 3 million data fields were 100% source data verified post hoc. An overall error rate of 0.45% was found. No sites had 0% errors. 100% SDV yielded an error rate of 0.27% as compared with partial SDV having an error rate of 0.53% (P < 0.0001). Comparing partly and fully monitored subjects, minor differences were identified between variables of major importance to efficacy or safety. ConclusionsThe findings challenge the notion that a 0% error rate is obtainable with on site monitoring. Data indicate consistently low error rates across the three trials analyzed. The use of complete vs. partial SDV offers a marginal absolute error rate reduction of 0.26%, i.e. a need to perform complete SDV of about 370 data points to avoid one unspecified error and does not support complete SDV as a means of providing meaningful improvements in data accuracy.
引用
收藏
页码:660 / 668
页数:9
相关论文
共 9 条
[1]   The potential for central monitoring techniques to replace on-site monitoring: findings from an international multi-centre clinical trial [J].
Bakobaki, Julie M. ;
Rauchenberger, Mary ;
Joffe, Nicola ;
McCormack, Sheena ;
Stenning, Sally ;
Meredith, Sarah .
CLINICAL TRIALS, 2012, 9 (02) :257-264
[2]  
EMA, 2014, REFL PAP RISK BAS QU
[3]  
FDA, 2014, GUID IND OV CLIN INV
[4]  
Food and Drug Administration, 1988, GUID IND GUID MON CL
[5]  
Funning S., 2009, QUAL ASSUR J, V12, P3, DOI DOI 10.1002/QAJ.433
[6]   Monitoring the quality of conduct of clinical trials: a survey of current practices [J].
Morrison, Briggs W. ;
Cochran, Chrissy J. ;
White, Jennifer Giangrande ;
Harley, Joan ;
Kleppinger, Cynthia F. ;
Liu, An ;
Mitchel, Jules T. ;
Nickerson, David F. ;
Zacharias, Cynthia R. ;
Kramer, Judith M. ;
Neaton, James D. .
CLINICAL TRIALS, 2011, 8 (03) :342-349
[7]   Improving the quality of drug research or simply increasing its cost? An evidence-based study of the cost for data monitoring in clinical trials [J].
Pronker, Esther ;
Geerts, Bart F. ;
Cohen, Adam ;
Pieterse, Herman .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (03) :467-470
[8]   Diagnosing the decline in pharmaceutical R&D efficiency [J].
Scannell, Jack W. ;
Blanckley, Alex ;
Boldon, Helen ;
Warrington, Brian .
NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (03) :191-200
[9]  
TransCelerate, 2013, RISK BAS MON METH